IRIS
PITINI, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.020
EU - Europa 2.415
AS - Asia 530
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
AF - Africa 1
Totale 5.974
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.017
IE - Irlanda 706
SE - Svezia 682
CN - Cina 447
UA - Ucraina 334
DE - Germania 202
GB - Regno Unito 133
FI - Finlandia 125
IT - Italia 105
SG - Singapore 51
BE - Belgio 39
RU - Federazione Russa 29
IN - India 18
CZ - Repubblica Ceca 16
FR - Francia 15
AT - Austria 11
NL - Olanda 7
IR - Iran 5
BR - Brasile 3
IL - Israele 3
JP - Giappone 3
NO - Norvegia 3
CA - Canada 2
EU - Europa 2
HK - Hong Kong 2
SK - Slovacchia (Repubblica Slovacca) 2
AM - Armenia 1
AU - Australia 1
CL - Cile 1
EE - Estonia 1
GR - Grecia 1
HU - Ungheria 1
LV - Lettonia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PT - Portogallo 1
RO - Romania 1
SC - Seychelles 1
Totale 5.974
Salva come PNG Salva come JPEG
Città #
Dublin 706
Jacksonville 651
Chandler 567
Nyköping 358
Beijing 204
Ashburn 161
Ann Arbor 156
Princeton 123
Cambridge 119
Des Moines 100
Dearborn 93
Medford 86
Boardman 70
Lancaster 61
Woodbridge 60
Messina 54
New York 40
Wilmington 39
Brussels 37
Jinan 34
Singapore 30
Los Angeles 29
Shenyang 26
San Mateo 22
Tianjin 22
Seattle 20
Houston 19
Ningbo 17
Brno 16
Nanjing 16
Haikou 14
Nanchang 14
Zhengzhou 14
Auburn Hills 13
Taizhou 13
Hebei 12
Vienna 11
Hangzhou 10
Hyderabad 8
Pune 8
Bremen 7
Guangzhou 7
Munich 7
Norwalk 7
Washington 7
Changsha 6
Chicago 6
Lanzhou 5
Leawood 5
Monmouth Junction 5
Santa Clara 5
Catania 4
Clearwater 4
Edinburgh 4
Helsinki 4
Las Vegas 4
Taiyuan 4
Bologna 3
Jiaxing 3
Kemerovo 3
Naples 3
Novokuznetsk 3
Oslo 3
Redwood City 3
Riva 3
Saint Petersburg 3
Scarsdale 3
Charlottesville 2
Dallas 2
Florence 2
Floridia 2
Fuzhou 2
Joinville 2
Lappeenranta 2
Milan 2
Montebelluna 2
Polomka 2
Santiago 2
Tappahannock 2
Tokyo 2
Trani 2
Uggiate Trevano 2
Waanrode 2
Amsterdam 1
Apo 1
Atlanta 1
Auckland 1
Baotou 1
Budapest 1
Central 1
Chengdu 1
Chongqing 1
Eden Prairie 1
Gaithersburg 1
Gostar 1
Groningen 1
Gurugram 1
Hanover 1
Hefei 1
Hongtong 1
Totale 4.223
Salva come PNG Salva come JPEG
Nome #
Should the Use of Surveillance Imaging in Diffuse Large B-Cell Lymphoma Be Discontinued? 95
Emerging markers of cachexia predict survival in cancer patients. 88
Bendamustine with Rituximab Is Safe and Effective As FRONT LINE Therapy in Elderly B-CLL Patients. an ITALIAN RETROSPECTIVE MULTICENTER Experience 87
Amplification and overexpression of the PSMB5 gene contributes to bortezomib resistance in retreatment of patients with multiple myeloma. 85
Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas 83
EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. 80
Beta=interferon in the treatment of 14 patie nts with advanced colorectal carcinoma. J Exp Pathol. 1987 Summer;3(4):603-5. No abstract available. PMID: 3454807 [PubMed - indexed for MEDLINE] 77
Trattamento endoscopico scleroterapico nelle neoplasie sanguinanti del tratto digestivo. 75
90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment. 74
CLINICAL ACTIVITY OF BORTEZOMIB IN RELAPSED OR REFRACTORY GASTRIC MARGINAL ZONE B-CELL LYMPHOMA OF MALT TYPE 73
An accessory spleen wrongly recognised as relapse by positron emission tomography 73
Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST 72
HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. 71
SUBCUTANEOUS LOW-DOSE ALEMTUZUMAB AS FIRST LINE THERAPY FOR ELDERLY CLL PATIENTS WITH DELETION OF 17p 67
AMIFOSTINE IN CONJUCTION WITH H.D. VP16 AND G-CSF ENABLE PBSC COLLECTION IN MULTIPLE MYELOMA PATIENTS WHO FAILED CTX INDUCED MOBILIZATION 66
Surgical treatment for congestive heart failure with autologous adult stem cell transplantation 66
An acute-leukaemia-like picture due to breast carcinoma cells. 65
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases 64
Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes 64
OUR EXPERIENCE ON THE EFFECTS OF TAMOXIFEN ON BLOOD COAGULATION IN PATIENTS OPERATED FOR BREAST CANCER Folia Oncologica vol.XIV-n.2-3 (Aprile-Settembre)-1991 63
CIRCULATING PLASMA CELLS IN MULTIPLE MYELOMA: CORRELATION WITH DISEASE STAGE 63
Systematic screening for HCV infection should be performed in patients with splenic marginal zone lymphoma 63
Amifostine in conjuction with G-CSF enhances chemoterapy mobilization of peripheral blood progenitor cell 63
Effect of treatment with amifostine in patients with myelodisplastic syndromes on clinical outcome and apoptosis in bone marrow 63
IMATINIB-INDUCED APOPTOSIS IN EOSINOPHILS OF PATIENTS WITH A HYPEREOSINOPHILIC SYNDROME PREDICTS RESPONSE TO TREATMENT 61
Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report 61
Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review. 61
A sequential chemoimmunotherapy protocol can obtain a high proportion of molecular remission in chronic lymphocytic leukaemia 60
90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVES SURVIVAL OF INTERMEDIATE/HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS NOT RESPONDING ADEQUATELY TO FIRST 60
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 59
Fatal delayed diagnosis in a patient with falciparum malaria 59
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study 59
Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy? 58
IMMUNOCHEMOTHERAPY WITH RITUXIMAB AND TEMOZOLOMIDE FOR CENTRAL NERVOUS SYSTEM LYMPHOMAS 58
Thyroid function, autoimmunity and nodules in hematological malignancies 58
Amplification and overexpression of the PSMB5 gene contribute to Bortezomib resistance in re-treatment of patients with Multiple Myeloma 57
AN UNUSUAL PRESENTATION OF SCHISTOSOMIASIS 56
Resistance to PGE(2) inhibition of PWM-stimulated lymphocytes from neoplastic patients 56
Endobronchial electrocautery for the dehydration of lung cancer. 56
Efficacy and Safety Of Bendamustine In Combination With Rituximab For Elderly Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia. A Retrospective Multicenter Study 55
Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease. 55
Myelodysplastic syndrome/acute myelogenous leukaemia after adjuvant chemotherapy with pyrimidine anti-metabolites in three patients 54
Severe pulmonary complications after bortezomib treatment for multiple myeloma: An unrecognized pulmonary vasculitis? 54
ANCHE IN VIVO IL PAMIDRONATO E' UN INDUTTORE DELLA APOPTOSI NELLE PLASMACELLULE MIELOMATOSE 54
Radiotherapy for stage I/II follicular lymphoma (FL): is it time for a re-appraisal? 53
MORPHOLOGICAL, PHENOTYPIC AND KARYOTYPIC CHARACTERIZATION OF A NOVEL NATURAL-KILLER-CELL TARGET - EVIDENCE OF INVOLVEMENT OF MHC CLASS-I MOLECULES IN NK CELL RECOGNITION 53
Spontaneous rupture of spleen during peripheral blood stem cell mobilization in a patient with breast cancer 53
Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options 53
Thyroid hormone autoantibodies: Are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? 53
Single-dose pegfilgrastim after chemotherapy is sufficient for mobilisation of peripheral blood stem cells in patients with multiple myeloma 52
Circulating plasma cells in Multiple Myeloma: correlation with disease stage 52
90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward? 52
Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease 51
Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. 51
Uso di Bortezomib come terapia di prima linea nella leucemia plasmacellulare primaria 50
Acute neurotoxicity as a serious adverse event related to rasburicase in a non-Hodgkin's lymphoma patient 50
DIABETIC FOOT DISEASE IN A PATIENT WITH MULTIPLE MYELOMA RECEIVING THALIDOMIDE 49
ALTE DOSI: QUESTIONI APERTE E SVILUPPI FUTURI 49
Extramedullary plasmacytoma presented as a non-functional invasive pituitary macro-adenoma. 49
ERLOTINIB IN A PATIENT WITH ACUTE MYELOGENOUS LEUKEMIA AND CONCOMITANT NON-SMALL-CELL LUNG CANCER 49
Temozolomide-induced shrinkage of a pituitary carcinoma. 49
SUCCESSFULL MOBILIZATION OF PERIPHERAL PROGENITOR CELLS WITH PACLITAXEL AND LENOGRASTIM PATIENTS WITH METASTATIC BREAST CANCER 48
Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report 48
Use of bisphosphonates in oncology 48
GENE EXPRESSION PROFILING DOES NOT IDENTIFY MOLECULAR SUBGROUP AMONG NODAL PERIPHERAL T-CELL LYMPHOMAS 47
IMPIEGO DELLA AMIFOSTINA NELLE PROCEDURE DI MOBILIZZAZIONE. NOSTRA ESPERIENZA 47
Salvage therapy for primary central nervous system lymphoma with Y-90-Ibritumomab and Temozolomide 47
Preliminary results of a phase II study of amifostine for patients with myelodisplastic syndrome 47
Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent 47
Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF 47
ERYTHROPOIETIN IN COMBINATION WITH LENOGRASTIM AFTER CYCLOPHOSPHAMIDE IMPROVES PERIPHERAL BLOOD PROGENITOR CELL YIELD IN MULTIPLE MYELOMA PATIENT 46
The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence 46
ADVERSE PROGNOSTIC FACTOR OF p53 GENE DELECTION DETECTED BY FISH IN MULTIPLE MYELOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION 46
Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option? 46
Association between XPD 312 single nucleotide polymorphism (SNP) and clinical outcome in stage IIIA-B non-small-cell lung cancer (NSCLC) patients (P) < 59 years (Y) treated with chemotherapy followed by surgery 46
Immunochemotherapy with temozolomide and rituximab for central nervous system lymphomas in an elderly population. 45
DASATINIB INDUCES A RESPONSE IN CHRONIC LYMPHOCYTIC LEUKEMIA 45
Circulating Mitotic Figures In A Patient With Dual Infection By Epstein-Barr Virus And Cytomegalovirus. 45
Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. 45
Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms 45
Pitfalls of positron emission tomography for assessing relapse in Hodgkin'sdisease: a case report 44
Sequential treatment with alemtuzumab and rituximab can induce long-term responses in splenic marginal zone lymphoma 44
STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma 44
Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: A surrogate marker of response? 43
How cells respond to interferons. 43
Risk of second malignant neoplasm among patients with lymphoma 43
Myeloid-derived suppressor cells absolute counts in predicting durable response to R-CHOP in patients with follicular lymphoma. 43
IMPIEGO DELLA AMIFOSTINE+HD VP16+G-CSF NEI PAZIENTI CON MIELOMA MULTIPLO CHE NON MOBILIZZANO DOPO CTX+G-CSF 42
Retrospective analysis of P-STAT6 expression as a predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate. 42
Single-dose of pegfilgrastim after chemotherapy is sufficient for mobilization of peripheral blood stem cells in patients with multiple myeloma 41
ANALISI SEQUENZIALE DELLA TRISOMIA 12 NELLA LEUCEMIA LINFATICA CRONICA 41
PIK3CA mutations in breast cancer: A potential predictive marker 41
LONG-TERM RESULTS FROM MOPPEBVCAD CHEMOTHERAPY WITH OPTIONAL LIMITED RADIOTHERAPY IN ADVANCED HODGKIN'S DISEASE 41
Efficacy and safety of bortezomib in patients with plasma cell leukemia 41
Personalized treatment of early-stage non-small-cell lung cancer: The challenging role of EGFR inhibitors 40
RESPONSE TO IMATINIB IN CHRONIC MYELOPROLIFERATIVE DISEASES WITH ACTIVATION OF THE PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR (PDGF betaR) 39
BORTEZOMIB AND PLASMA CELL LEUKEMIA 39
MOPP EBV CAD HYBRID CHEMOTHERAPY WITH OR WITHOUT LIMITED RADIOTHERAPY IN ADVANCED OR UNFAVORABLY PRESENTING HODGKINS- DISEASE - A REPORT FROM THE ITALIAN-LYMPHOMA-STUDY-GROUP 38
MYELODYSPLASTIC SYNDROMES DEVELOPING DURING IMATINIB THERAPY FOR GIST 38
Retrospective analysis of P-STAT6 expression as a predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 37
Totale 5.464
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.549
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.549
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020844 0 89 7 85 7 78 145 117 9 163 140 4
2020/2021767 118 4 199 36 32 96 8 84 16 89 57 28
2021/2022848 6 139 18 17 25 3 58 27 5 160 154 236
2022/20232.164 173 209 102 170 187 205 23 136 855 9 71 24
2023/2024445 38 88 29 57 28 83 14 34 3 22 3 46
2024/202549 28 21 0 0 0 0 0 0 0 0 0 0
Totale 6.097